Skip to main content
Erschienen in: Drug Safety 4/2013

01.04.2013 | Original Research Article

Effect of Pharmacist Involvement on Patient Reporting of Adverse Drug Reactions: First Italian Study

verfasst von: Roberto Leone, Ugo Moretti, Paola D’Incau, Anita Conforti, Lara Magro, Riccardo Lora, Giampaolo Velo

Erschienen in: Drug Safety | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Adding patients to the range of potential reporters of adverse drug reactions (ADRs) may increase spontaneous reporting and contribute to the detection of signals, one of the primary aims of spontaneous reporting systems. Community pharmacies could have an important role in this context as a service for promoting patient reporting of ADRs.

Objectives

The main objectives of the present study were to assess the potential impact of an intervention to promote patient reporting in community pharmacies in the Veneto region of Italy, and to compare the characteristics of patients’ and general practitioners’ (GPs) reports of ADRs.

Methods

The study was conducted in the Veneto region of Italy and involved 211 pharmacists working in 118 community pharmacies. Each pharmacist was asked to select, during the study period, about 250 customers who had received at least one drug, and then to present the spontaneous reporting form to those who had experienced a suspected ADR. Patients were asked to complete the ADR report form and either give it back to the pharmacist, or send it by fax or mail, or else to fill in the form online.

Results

In a 4-month period, 52,495 customers were interviewed by the pharmacists and 4,949 of them (9.4 %) referred a suspected ADR. The Pharmacovigilance Centre of the Veneto region received 2,311 citizen’s ADR reporting forms related to the study (from 46.7 % of all patients interviewed who had experienced suspected ADRs). After quality control 1,794 of these reports were entered into the Italian Pharmacovigilance Database and were compared with the reports (226) sent by GPs in the Veneto region in the same period. Patients reported a higher percentage of known and non-serious reactions than did GPs. Drugs widely used in the community setting, and over-the-counter products, were the drugs most frequently reported by patients. In contrast, few reports involving reactions to antineoplastic agents or contrast media—drugs mostly used in a hospital setting—were sent by patients.

Conclusions

Our study shows that patient reporting has the potential to add value to the pharmacovigilance system. The overall quality of the information provided in patients’ reports was good. The differences between reports by patients and by GPs indicate different points of view that can enrich spontaneous reporting.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat McLernon DJ, Bond CM, Lee AJ, et al. Patient views and experiences of making adverse drug reaction reports to the Yellow Card Scheme in the UK. Pharmacoepidemiol Drug Saf. 2011;20:523–31.PubMedCrossRef McLernon DJ, Bond CM, Lee AJ, et al. Patient views and experiences of making adverse drug reaction reports to the Yellow Card Scheme in the UK. Pharmacoepidemiol Drug Saf. 2011;20:523–31.PubMedCrossRef
2.
Zurück zum Zitat McLernon DJ, Bond CM, Hannaford PC, et al. Yellow card collaboration: adverse drug reaction reporting in the UK. A retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals. Drug Saf. 2010;33(9):775–88.PubMedCrossRef McLernon DJ, Bond CM, Hannaford PC, et al. Yellow card collaboration: adverse drug reaction reporting in the UK. A retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals. Drug Saf. 2010;33(9):775–88.PubMedCrossRef
3.
Zurück zum Zitat van Hunsel F, van der Welle C, Passier A, et al. Motives for reporting adverse drug reactions by patient-reporters in the Netherlands. Eur J Clin Pharmacol. 2010;66:1143–50.PubMedCrossRef van Hunsel F, van der Welle C, Passier A, et al. Motives for reporting adverse drug reactions by patient-reporters in the Netherlands. Eur J Clin Pharmacol. 2010;66:1143–50.PubMedCrossRef
4.
Zurück zum Zitat van Hunsel F, Talsma A, van Puijenbroek E, et al. The proportion of patient reports of suspected ADRs to signal detection in the Netherlands: case-control study. Pharmacoepidemiol Drug Saf. 2011;20:286–91.PubMedCrossRef van Hunsel F, Talsma A, van Puijenbroek E, et al. The proportion of patient reports of suspected ADRs to signal detection in the Netherlands: case-control study. Pharmacoepidemiol Drug Saf. 2011;20:286–91.PubMedCrossRef
5.
Zurück zum Zitat Aagaard L, Nielsen LH, Hansen EH. Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006. Drug Saf. 2009;32:1067–74.PubMedCrossRef Aagaard L, Nielsen LH, Hansen EH. Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006. Drug Saf. 2009;32:1067–74.PubMedCrossRef
6.
Zurück zum Zitat Aagaard L, Hansen EH. Consumers’ reports of suspected adverse drug reactions volunteered to a consumer magazine. Br J Clin Pharmacol. 2010;69:317–8.PubMedCrossRef Aagaard L, Hansen EH. Consumers’ reports of suspected adverse drug reactions volunteered to a consumer magazine. Br J Clin Pharmacol. 2010;69:317–8.PubMedCrossRef
7.
Zurück zum Zitat Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med. 2010;362:865–9.PubMedCrossRef Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med. 2010;362:865–9.PubMedCrossRef
8.
Zurück zum Zitat Blenkinsopp A, Wilkie P, Wang M, et al. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol. 2007;63:148–56.PubMedCrossRef Blenkinsopp A, Wilkie P, Wang M, et al. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol. 2007;63:148–56.PubMedCrossRef
9.
Zurück zum Zitat de Langen J, van Hunsel F, Passier A, et al. Adverse drug reaction reporting by patients in the Netherlands: three years of experience. Drug Saf. 2008;31:515–24.PubMedCrossRef de Langen J, van Hunsel F, Passier A, et al. Adverse drug reaction reporting by patients in the Netherlands: three years of experience. Drug Saf. 2008;31:515–24.PubMedCrossRef
10.
Zurück zum Zitat Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29:385–96.PubMedCrossRef Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29:385–96.PubMedCrossRef
11.
Zurück zum Zitat Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009;32(1):19–31.PubMedCrossRef Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009;32(1):19–31.PubMedCrossRef
12.
Zurück zum Zitat van Grootheest K, de Graaf L, de Jong-van den Berg LT. Consumer adverse drug reaction reporting: a new step in pharmacovigilance? Drug Saf 2003; 26(4): 211–7. van Grootheest K, de Graaf L, de Jong-van den Berg LT. Consumer adverse drug reaction reporting: a new step in pharmacovigilance? Drug Saf 2003; 26(4): 211–7.
15.
Zurück zum Zitat van Hunsel F, Härmark L, Pal S, et al. Experiences with adverse drug reaction reporting by patients: an 11-country survey. Drug Saf. 2012;35(1):45–60.PubMedCrossRef van Hunsel F, Härmark L, Pal S, et al. Experiences with adverse drug reaction reporting by patients: an 11-country survey. Drug Saf. 2012;35(1):45–60.PubMedCrossRef
16.
Zurück zum Zitat Italian Legislative Decree 20 April 1991. Document Information Ministry (Gazzetta Ufficiale) No. 133/1991. Italian Legislative Decree 20 April 1991. Document Information Ministry (Gazzetta Ufficiale) No. 133/1991.
18.
19.
Zurück zum Zitat Planas LG, Kimberlin CL, Segal R, et al. A pharmacist model of perceived responsibility for drug therapy outcomes. Soc Sci Med. 2005;60:2393–403.PubMedCrossRef Planas LG, Kimberlin CL, Segal R, et al. A pharmacist model of perceived responsibility for drug therapy outcomes. Soc Sci Med. 2005;60:2393–403.PubMedCrossRef
20.
Zurück zum Zitat Bell JS, Whitehead P, Aslani P, et al. Design and implementation of an educational partnership between community pharmacists and consumer educators in mental health care. Am J Pharm Educ. 2006;70(2):28.PubMedCrossRef Bell JS, Whitehead P, Aslani P, et al. Design and implementation of an educational partnership between community pharmacists and consumer educators in mental health care. Am J Pharm Educ. 2006;70(2):28.PubMedCrossRef
21.
Zurück zum Zitat Thomsen LA, Winterstein AG, Søndergaard B, et al. Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother. 2007;41(9):1411–26.PubMedCrossRef Thomsen LA, Winterstein AG, Søndergaard B, et al. Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother. 2007;41(9):1411–26.PubMedCrossRef
22.
Zurück zum Zitat Italian Legislative Decree 12 December 2003. Document Information Ministry (Gazzetta Ufficiale) No.36/2004. Italian Legislative Decree 12 December 2003. Document Information Ministry (Gazzetta Ufficiale) No.36/2004.
24.
Zurück zum Zitat Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.PubMedCrossRef Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.PubMedCrossRef
26.
Zurück zum Zitat Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109–17.PubMedCrossRef Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109–17.PubMedCrossRef
29.
Zurück zum Zitat Borg J-J, Aislaitner G, Pirozynski M, et al. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance. Drug Saf. 2011;34(3):187–97.PubMedCrossRef Borg J-J, Aislaitner G, Pirozynski M, et al. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance. Drug Saf. 2011;34(3):187–97.PubMedCrossRef
30.
Zurück zum Zitat Taché SV, Sönnichsen A, Ashcroft DM. Prevalence of adverse drug events in ambulatory care: a systematic review. Ann Pharmacother. 2011;45:977–89.PubMedCrossRef Taché SV, Sönnichsen A, Ashcroft DM. Prevalence of adverse drug events in ambulatory care: a systematic review. Ann Pharmacother. 2011;45:977–89.PubMedCrossRef
31.
Zurück zum Zitat Franconi F, Brunelleschi S, Steardo L, et al. Gender differences in drug responses. Pharmacol Res. 2007;55:81–95.PubMedCrossRef Franconi F, Brunelleschi S, Steardo L, et al. Gender differences in drug responses. Pharmacol Res. 2007;55:81–95.PubMedCrossRef
32.
Zurück zum Zitat Zopf Y, Rabe C, Neubert A, et al. Women encounter ADRs more often than do men. Eur J Clin Pharmacol. 2008;64:999–1004.PubMedCrossRef Zopf Y, Rabe C, Neubert A, et al. Women encounter ADRs more often than do men. Eur J Clin Pharmacol. 2008;64:999–1004.PubMedCrossRef
33.
Zurück zum Zitat Avery AJ, Anderson C, Bond CM, et al. Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow Card Scheme’: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011; 15: 1–234, iii–iv. Avery AJ, Anderson C, Bond CM, et al. Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow Card Scheme’: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011; 15: 1–234, iii–iv.
35.
Zurück zum Zitat Fortnum H, Lee AJ, Rupnik B, et al. Survey to assess public awareness of patient reporting of adverse drug reactions in Great Britain. J Clin Pharm Ther. 2012;37:161–5.PubMedCrossRef Fortnum H, Lee AJ, Rupnik B, et al. Survey to assess public awareness of patient reporting of adverse drug reactions in Great Britain. J Clin Pharm Ther. 2012;37:161–5.PubMedCrossRef
36.
Zurück zum Zitat Lorimer S, Cox A, Langford NJ. A patient’s perspective: the impact of adverse drug reactions on patients and their views on reporting. J Clin Pharm Ther. 2012;37:148–52.PubMedCrossRef Lorimer S, Cox A, Langford NJ. A patient’s perspective: the impact of adverse drug reactions on patients and their views on reporting. J Clin Pharm Ther. 2012;37:148–52.PubMedCrossRef
37.
Zurück zum Zitat Mitchell AS, Henry DA, Sanson-Fisher R, et al. Patients as a direct source of information on adverse drug reactions. BMJ. 1988;297:891–3.PubMedCrossRef Mitchell AS, Henry DA, Sanson-Fisher R, et al. Patients as a direct source of information on adverse drug reactions. BMJ. 1988;297:891–3.PubMedCrossRef
38.
Zurück zum Zitat Jarernsiripornkul N, Kakaew W, Loalukkana W, et al. Adverse drug reaction monitoring: comparing doctor and patient reporting for new drugs. Pharmacoepidemiol Drug Saf. 2009;18:240–5.PubMedCrossRef Jarernsiripornkul N, Kakaew W, Loalukkana W, et al. Adverse drug reaction monitoring: comparing doctor and patient reporting for new drugs. Pharmacoepidemiol Drug Saf. 2009;18:240–5.PubMedCrossRef
39.
Zurück zum Zitat van Hunsel F, Passier A, van Grootheest K. Comparing patients’ and healthcare professionals’ ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and risks of statins as an example. Br J Clin Pharmacol. 2009;67:558–64.PubMedCrossRef van Hunsel F, Passier A, van Grootheest K. Comparing patients’ and healthcare professionals’ ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and risks of statins as an example. Br J Clin Pharmacol. 2009;67:558–64.PubMedCrossRef
40.
Zurück zum Zitat Krska J, Anderson C, Murphy E, et al. How patient reporters identify adverse drug reactions: a qualitative study of reporting via the UK Yellow Card Scheme. Drug Saf. 2011;34:429–36.PubMedCrossRef Krska J, Anderson C, Murphy E, et al. How patient reporters identify adverse drug reactions: a qualitative study of reporting via the UK Yellow Card Scheme. Drug Saf. 2011;34:429–36.PubMedCrossRef
43.
Zurück zum Zitat Inch J, Watson MC, Anakwe-Umeh S. Patient versus healthcare professional spontaneous adverse drug reaction reporting: a systematic review. Drug Saf. 2012;35:807–18.PubMed Inch J, Watson MC, Anakwe-Umeh S. Patient versus healthcare professional spontaneous adverse drug reaction reporting: a systematic review. Drug Saf. 2012;35:807–18.PubMed
Metadaten
Titel
Effect of Pharmacist Involvement on Patient Reporting of Adverse Drug Reactions: First Italian Study
verfasst von
Roberto Leone
Ugo Moretti
Paola D’Incau
Anita Conforti
Lara Magro
Riccardo Lora
Giampaolo Velo
Publikationsdatum
01.04.2013
Verlag
Springer International Publishing AG
Erschienen in
Drug Safety / Ausgabe 4/2013
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-013-0028-8

Weitere Artikel der Ausgabe 4/2013

Drug Safety 4/2013 Zur Ausgabe